Imagion Biosystems (ASX:IBX) has announced the appointment of Dr Isaac Bright as its new CEO.
Dr Bright brings over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics.
“We are very pleased to have attracted someone of Dr Bright’s calibre to Imagion,” said chairman Bob Proulx.
“As we move into this next phase of our business, building on the success we have achieved to date with our MagSense nanoparticle technology, Dr Bright’s track record in strategic partnering, financing, and M&A are well suited to support our vision and drive the next chapter in Imagion’s growth. I’m looking forward to working with Dr Bright to build value for our shareholders and we are excited to have him become part of our team.”
“Imagion Biosystems is a pioneer in clinical molecular imaging and nanoparticle innovation, and I look forward to working with the board and my new colleagues as we grow and advance our clinical pipeline and capabilities.” said Dr Bright.
“I am thrilled to be leading the Imagion team and look forward to driving the company’s continued success with new solutions for cancer patients and their care teams.”
“We have been very encouraged by the quality of candidates that we have seen during the recruitment process,” said Dianne Angus, chair of the remuneration and nomination committee. “It was essential to attract an executive with both scientific and business competence to drive product development to commercialisation."